Teva Pharmaceutical Industries (NYSE:TEVA) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a hold rating in a research note released on Thursday morning.

Several other brokerages also recently weighed in on TEVA. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Down 2.8 %

Shares of TEVA stock opened at $15.06 on Thursday. The stock’s 50 day simple moving average is $17.21 and its 200 day simple moving average is $18.12. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market capitalization of $17.07 billion, a price-to-earnings ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Pathstone Holdings LLC lifted its stake in Teva Pharmaceutical Industries by 6.5% during the third quarter. Pathstone Holdings LLC now owns 72,598 shares of the company’s stock worth $1,308,000 after purchasing an additional 4,452 shares during the period. Intech Investment Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $439,000. Charles Schwab Investment Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 24.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company’s stock worth $16,203,000 after buying an additional 177,836 shares during the period. Daiwa Securities Group Inc. boosted its stake in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 89,465 shares of the company’s stock valued at $1,612,000 after buying an additional 8,100 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Teva Pharmaceutical Industries by 5.9% in the third quarter. The Manufacturers Life Insurance Company now owns 432,402 shares of the company’s stock valued at $7,792,000 after acquiring an additional 24,248 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.